Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Amy B. Goodale"'
Autor:
Tikvah K. Hayes, Elisa Aquilanti, Nicole S. Persky, Xiaoping Yang, Erica E. Kim, Lisa Brenan, Amy B. Goodale, Douglas Alan, Ted Sharpe, Robert E. Shue, Lindsay Westlake, Lior Golomb, Brianna R. Silverman, Myshal D. Morris, Ty Running Fisher, Eden Beyene, Yvonne Y. Li, Andrew D. Cherniack, Federica Piccioni, J. Kevin Hicks, Andrew S. Chi, Daniel P. Cahill, Jorg Dietrich, Tracy T. Batchelor, David E. Root, Cory M. Johannessen, Matthew Meyerson
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract The epidermal growth factor receptor, EGFR, is frequently activated in lung cancer and glioblastoma by genomic alterations including missense mutations. The different mutation spectra in these diseases are reflected in divergent responses to
Externí odkaz:
https://doaj.org/article/0edde2f4b771457398e829246efe16d1
Autor:
Tikvah K. Hayes, Elisa Aquilanti, Nicole S. Persky, Xiaoping Yang, Erica E. Kim, Lisa Brenan, Amy B. Goodale, Douglas Alan, Ted Sharpe, Robert E. Shue, Lindsay Westlake, Lior Golomb, Brianna R. Silverman, Myshal D. Morris, Ty Running Fisher, Eden Beyene, Yvonne Y. Li, Andrew D. Cherniack, Federica Piccioni, J. Kevin Hicks, Andrew S. Chi, Daniel P. Cahill, Jorg Dietrich, Tracy T. Batchelor, David E. Root, Cory M. Johannessen, Matthew Meyerson
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/c60cde2e831e452ca04b334e2136cd27
Autor:
Cory M. Johannessen, Matthew Meyerson, Levi A. Garraway, David E. Root, Federica Piccioni, Mukta Bagul, Sasha Pantel, Yenarae Lee, Amy B. Goodale, Ofir Cohen, Flora Luo, Tikvah K. Hayes
Combinatorial inhibition of MEK1/2 and CDK4/6 is currently undergoing clinical investigation in NRAS-mutant melanoma. To prospectively map the landscape of resistance to this investigational regimen, we utilized a series of gain- and loss-of-function
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31ccb0a4f12fd3f443da00c9ef0ad312
https://doi.org/10.1158/0008-5472.c.6511556.v1
https://doi.org/10.1158/0008-5472.c.6511556.v1
Autor:
Cory M. Johannessen, Matthew Meyerson, Levi A. Garraway, David E. Root, Federica Piccioni, Mukta Bagul, Sasha Pantel, Yenarae Lee, Amy B. Goodale, Ofir Cohen, Flora Luo, Tikvah K. Hayes
SF1: NRAS mutant melanoma sensitivity to trametinib and palbociclib treatment; SF2: MELJUSO ORF Screen Optimization and Validation; SF3: MELJUSO CRISPR Screen Optimization and Validation; SF4: EGFR-PI3K-AKT signaling modulates resistance to trametini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6320e445c30be16fd2a43e4d82607b70
https://doi.org/10.1158/0008-5472.22423682
https://doi.org/10.1158/0008-5472.22423682